Our strategy

Our strategy is based on an integrated business model that has allowed us to build a portfolio of differentiated clinical and pre-clinical assets as well as a growing commercial business.

We are focused on utilizing our proven and validated product development capabilities to rapidly advance solutions addressing unmet needs in infectious diseases towards regulatory approval, with the goal of becoming first-, best- or only-in-class. We have entered into strategic partnerships with other well-established pharmaceutical companies to leverage their clinical and commercial capabilities to optimize the potential value of select assets. As we advance our late-stage portfolio, we also remain focused on investing in our research and development pipeline in order to develop our earlier stage assets as well as identify new targets and indications where we believe we can make a significant difference.

In order to execute upon this strategy as an independent, financially sustainable company, we are pursuing the following strategic goals:

• Advance VLA15 for the prevention of Lyme disease in collaboration with Pfizer.
• Grow product sales focusing on proprietary products and build a leading position in the travel vaccines market.
• Progress our pipeline of clinical and pre-clinical programs to develop new vaccines addressing diseases with significant unmet need.
• Opportunistically pursue strategic collaborations to maximize full potential of our clinical and commercial portfolios.
• Become an ESG (environmental, social, and governance)-focused enterprise.